Progranulin

Progranulin Molekülinformation

Englischer Name	Progranulin	Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	7	Target-Alias	GRN
Höchste Forschungs- und Entwicklungsphase	Phase 2 Clinical

Englischer Name	Progranulin
Target-Alias	GRN
Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	7
Höchste Forschungs- und Entwicklungsphase	Phase 2 Clinical

Progranulin Produktliste

Attribut
Protein (1)
Produktbibliothek
Online (1)
Spezies
Human (1)
Etikett
His Tag (1)
Marker
Unconjugated (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
PGN-H52H3	Human	HEK293	Human Progranulin Protein, His Tag, low endotoxin (MALS & SPR verified)				In den Warenkorb legen

Gesamtmenge1

Progranulin Molekülhintergrund

Progranulin, a secreted glycoprotein, is encoded in humans by the single GRN gene. Progranulin consists of seven and a half, tandemly repeated, non-identical copies of the 12 cysteine granulin motif. Many cellular processes and diseases are associated with this unique pleiotropic factor that include, but are not limited to, embryogenesis, tumorigenesis, inflammation, wound repair, neurodegeneration and lysosome function. Haploinsufficiency caused by autosomal dominant mutations within the GRN gene leads to frontotemporal lobar degeneration, a progressive neuronal atrophy that presents in patients as frontotemporal dementia.

Progranulin Molekülalias

CLN11, GEP, GP88, PCDGF, PEPI, PGRN

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
GRN Gene Therapy（Eli Lilly And Company）	PR-006; LY3884963	Phase 2 Clinical	Eli Lilly And Company	Frontotemporal Dementia	Details
TAK-594	DNL-593; PTV:PGRN; TAK-594	Phase 2 Clinical	Denali Therapeutics Inc	Frontotemporal Dementia	Details
AVB-101	AVB-101	Phase 2 Clinical	AviadoBio Ltd	Frontotemporal Dementia	Details
Nivisnebart	AL-101; GSK-4527226	Phase 2 Clinical	Alector Inc	Alzheimer Disease; Amyotrophic Lateral Sclerosis; Frontotemporal Dementia; Nerve Degeneration; Parkinson Disease	Details
PBFT-02	PBFT-02	Phase 2 Clinical	University Of Pennsylvania	Frontotemporal Dementia	Details
VGN-R13	VGN-R13	Phase 1 Clinical	Shanghai Vitalgen BioPharma Co Ltd	Amyotrophic Lateral Sclerosis	Details
AG-01（A&G Pharm）	AG-01（A&G Pharm）	Phase 1 Clinical	A&G Pharmaceutical	Carcinoma, Non-Small-Cell Lung; Mesothelioma; Triple Negative Breast Neoplasms	Details